Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension

Journal of Clinical Sleep Medicine

Volumn 6, Issue 4, 2010, Pages 363-368

  Gonzaga, Carolina C ^a   Gaddam, Krishna K ^a   Ahmed, Mustafa I ^a   Pimenta, Eduardo ^b   Thomas, S Justin ^a   Harding, Susan M ^c   Oparil, Suzanne ^a   Cofield, Stacey S ^c   Calhoun, David A ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Aldosterone; Cardiovascular disease; Obstructive sleep apnea; Resistant hypertension; Sleep disorder

Indexed keywords

ALDOSTERONE;

ALDOSTERONE BLOOD LEVEL; ALDOSTERONE URINE LEVEL; APNEA HYPOPNEA INDEX; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; POLYSOMNOGRAPHY; PROSPECTIVE STUDY; SLEEP APNEA SYNDROME;

EID: 77956278931     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.27878     Document Type: Article

References (34)

1. Shamsuzzaman ASM, Gersh BJ, Somers VK. Obstructive sleep apnea. Implications for cardiac and vascular disease. JAMA 2003;290:1906-14.
2. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as risk factor for stroke and death. N Engl J Med 2005;353:2034-41. (Pubitemid 41609096)
3. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease. Am J Respir Crit Care Med 2001;163:19-25.
4. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin Sleep Cohort. Sleep 2008;31:1071-8.
5. Kuniyoshi FHS, Garcia-Touchard A, Garni AS, et al. Day-night variation of acute myocardial infarction in obstructive sleep apnea. J Am Coll Cardiol 2008;52:343-6.
6. Marin JM, Carrizo SJ, Vicente E, Agusti AGN. Lon-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046-53. (Pubitemid 40386782)
7. Somers VK, White DP, Amin R, et al; American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology; American Heart Association Stroke Council; American Heart Association Council on Cardiovascular Nursing; American College of Cardiology Foundation. Sleep Apnea and Cardiovascular Disease: an American Heart Association/American College of Cardiology Foundation scientific statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing Council. Circulation 2008;118:1080-111.
8. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378-84. (Pubitemid 30262394)
9. Kales A, Bixler EO, Cadieux RJ, et al. Sleep apnea in hypertensive population. Lancet 1984;2:1005-8.
10. Lavie P, Ben-Yosef R, Rubin AE. Prevalence of sleep apnea syndrome among patients with essential hypertension. Am Heart J 1984;108:373-6.
11. Williams AJ, Houston D, Finberg S, Lam C, Kinney JL, Santiago S. Sleep apnea syndrome and essential hypertension. Am J Cardiol 1985;55:1019-22. (Pubitemid 15085355)
12. Calhoun DA, Jones D, Textor S, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19.
13. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J Hypertens 2001;19:2271-7.
14. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007;131:453-9.
15. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004;22:2217-26.
16. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003;17:349-52. (Pubitemid 36625965)
17. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension. Association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008;168:1159-64.
18. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40:892-6.
19. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004;125:112-7.
20. Mattsson C, Young Jr WF. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006;2:198-208.
21. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:3266-81.
22. Rechtschaffen A, Kales A, eds. A manual of standardized terminology, techniques, and scoring system for sleep stages of human sleep. Los Angeles: Brain Information Service/ Brain Research Institute, UCLA, 1968.
23. Shiota S, Ryan CM, Chiu KL, et al. Alterations in upper airway cross-sectional area in response to lower body positive pressure in healthy subjects. Thorax 2007;62:868-72.
24. Bucca CB, Brussino L, Battisti A, et al. Diuretics in obstructive sleep apnea with diastolic heart failure. Chest 2007;132:440-6. (Pubitemid 47282374)
25. Schwab RJ, Pasirstein M, Pierson R, et al. Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. Am J Respir Crit Care Med 2003;168:522-30.
26. Patil SP, Schneider H, Schwartz AR, Smith PL. Adult obstructive sleep apnea. Pathophysiology and diagnosis. Chest 2007;132,325-7.
27. Wolk R, Johnson BD, Somers VK. Leptin and the ventilatory response to exercise in heart failure. J Am Coll Cardiol 2003;42:1644-9.
28. Somers VK, Mark AL, Zavala DC, Abboud FM. Influence of ventilation and hypocapnia on sympathetic nerve responses to hypoxia in normal humans. J Appl Physiol 1989;67:2095-100.
29. Somers VK, Mark AL, Zavala DC, Abboud FM. Contrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humans. J Appl Physiol 1989;67:2101-6.
30. Zhang ZH, Yu Y, Kang YM, Wei SG, Felder RB. Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am J Physiol Heart Circ Physiol 2008;294:H1067-74.
31. Møller DS, Lind P, Strunge B, Pedersen EB. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens 2003;16:274-80. (Pubitemid 36384754)
32. Boström KB, Hedner J, Melander O, et al. Interaction between the angiotensin-converting enzyme gene insertion/deletion polymorphism and obstructive sleep apnoea as a mechanism for hypertension. J Hypertens 2007;25:779-83.
33. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosteronerenin ratio. Am J Kidney Dis 2001;37:669-705.
34. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma rennin activity ratio in primary aldosteronism. Hypertension 2002;40:897-902.